Bendamustine 50 mg is a unique alkylating agent, which combines a nitrogen mustard moiety of mechlorethamine with a benzimidazole. The bendamustine 50 mg injection has shown promising clinical activity against a range of hematologic malignancies and solid tumors as a single agent or along with certain other anticancer agents. This medicinal product is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and for indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed while on or within 6 months of therapy with rituximab or a rituximab-containing regimen. Like other existing alkylating agents, bendamustine injection causes cross-links between DNA bases, resulting in DNA damage. In order to place an enquiry for bendamustine 50 mg, kindly connect at TOLL-FREE: 1800-889-1064.